Nucleated cells lacking CD45 and expressing cytokeratin were classified as circulating tumor cells. The use of circulating tumor DNA diagnostics to identify cancer reduces the requirement for sample tumor tissue, such as tumor biopsy. Tumor DNA diagnostics in the blood are also used to guide tumor-specific treatment. This strategy aids the clinician in determining the most appropriate cancer treatment option.
Frequently Asked Questions
The market is segmented based on Global Circulating Tumor DNA (ctDNA) Market Segmentation, By Application (Routine Screening, Patient Work Up, Early-Stage Disease, Late Stage/Metastatic Disease), Sample (Blood, Urine, Others), Method (Sample Preparation, Ultra-Low Passage Whole Genome Sequencing, ctDNA Quantification, Copy Number Analysis, Statistical Analysis), End-Users (Hospitals, Research Laboratories, Academia, Research Centers) – Industry Trends and Forecast to 2032
.
The Global Circulating Tumor Dna Ctdna Market size was valued at USD 19.76 USD Billion in 2024.
The Global Circulating Tumor Dna Ctdna Market is projected to grow at a CAGR of 17% during the forecast period of 2025 to 2032.
The major players operating in the market include GRAIL , Guardant Health, Biodesix, Freenome Holdings , LungLife AI , Inivata Ltd, Personal Genome Diagnostics , CellMax Life, Vermillion orporated, Genomic Health , Foundation Medicine , Biocept , Myriad Genetics , OncoCyte, Veracyte .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
